中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

1002 records (took 0.132 seconds)

    Synthethic peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus
    383.
    发明申请
    Synthethic peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus 审中-公开
    合成肽和包含它们的药物组合物用于治疗系统性红斑狼疮

    公开(公告)号：US20040235729A1

    公开(公告)日：2004-11-25

    申请号：US10620621

    申请日：2003-07-17

    Applicant: Yeda Research and Development Co. Ltd.

    Inventor： Edna Mozes ,  Ari Waisman

    IPC: A61K038/10 ,  A61K038/08

    CPC classification number: G01N33/564 ,  A61K38/00 ,  A61K47/62 ,  C07K16/18 ,  C07K2317/73 ,  G01N2800/104

    Abstract: Synthetic peptides based on a complementarity-determining region (CDR) of the heavy or light chain of a pathogenic anti-DNA monoclonal antibody that induces a systemic lupus erythematosus (SLE)-like disease in mice, and analogs, and salts and chemical derivatives thereof; dual peptides comprising two such peptides or analogs covalently linked to one another either directly or through a short linking chain; peptide polymers comprising a plurality of sequences of said peptide or analog thereof; and peptide polymers attached to a macromolecular carrier, are disclosed, and pharmaceutical compositions comprising them for the treatment of SLE in humans.

    Abstract translation: 基于诱导小鼠系统性红斑狼疮（SLE）样疾病的病原性抗DNA单克隆抗体的重链或轻链的互补决定区（CDR）的合成肽及其类似物及其盐及其化学衍生物 ; 包含两个这样的肽的双肽或直接或通过短连接链彼此共价连接的类似物; 包含所述肽或其类似物的多个序列的肽聚合物; 和与大分子载体连接的肽聚合物，以及包含它们的药物组合物用于治疗人类中的SLE。

    Avidin derivatives and uses thereof
    385.
    发明申请
    Avidin derivatives and uses thereof 失效
    抗生物素蛋白衍生物及其用途

    公开(公告)号：US20040191832A1

    公开(公告)日：2004-09-30

    申请号：US10624503

    申请日：2003-07-23

    Applicant: YEDA RESEARCH AND DEVELOPMENT CO., LTD.

    Inventor： Meir Wilchek ,  Edward A. Bayer ,  Heike Hofstetter ,  Margherita Morpurgo

    IPC: G01N033/53

    CPC classification number: C07K14/465 ,  G01N33/532 ,  G01N33/583

    Abstract: A covalent conjugate of a 4null-hydroxyazobenzene-2-carboxylic acid. derivative (HABA) and an avidin-type molecule, of the formula: 1 wherein A is (CH2)n or nullCHnullCHnull, wherein n is an integer from 0-10; B is (CH2)n wherein n is an integer from 2 to 10; m is zero or 1; and Av is the residue of an avidin-type molecule selected from the group comprising native egg-white avidin, recombinant avidin, deglycosylated avidins, bacterial streptavidin, recombinant streptavidin, truncated streptavidin and other derivatives of said avidin-type molecules. These HABAylated avidins are red colored in the quinone configuration and can be used in many applications in the avidin-biotin technology.

    Abstract translation: 4'-羟基偶氮苯-2-羧酸的共价缀合物。 衍生物（HABA）和抗生物素蛋白型分子，其中A是（CH 2）n或-CH = CH-，其中n是0-10的整数; B是（CH 2）n，其中n是2至10的整数; m为零或1; Av是选自天然蛋白抗生物素蛋白，重组抗生物素蛋白，去糖基化抗体，细菌链霉抗生物素蛋白，重组链霉抗生物素蛋白，截短的链霉抗生物素蛋白和所述抗生物素蛋白型分子的其它衍生物的组的抗生物素蛋白型分子的残基。 这些HABA化的avidins在醌配体中是红色的，并且可以用于抗生物素蛋白 - 生物素技术的许多应用。

    Central nervous system-derived immune privilege factor and uses thereof
    386.
    发明申请
    Central nervous system-derived immune privilege factor and uses thereof 审中-公开
    中枢神经系统衍生的免疫特权因子及其用途

    公开(公告)号：US20040142860A1

    公开(公告)日：2004-07-22

    申请号：US09814699

    申请日：2001-03-23

    Applicant: Yeda Research and Development Co. Ltd.

    Inventor： Michal Eisenbach-Schwartz ,  Pierre Beserman ,  David L. Hirschberg

    IPC: A61K038/17 ,  C07K014/74

    CPC classification number: C07K5/06104 ,  A61K38/00 ,  C07K4/12 ,  Y02A50/465

    Abstract: The present invention is directed to a central nervous system-derived heat stable immune privilege factor which exerts an inhibitory effect on macrophage migration and/or macrophage phagocytic activity. In addition, the factor exerts an inhibitory effect on the ability of macrophages and T cells to adhere to extracellular matrix and/or fibronectin. The invention is also directed to the isolation and methods for use of this immune privilege factor for the inhibition of inflammation in the central nervous system generally and at specific lesions in the central nervous system.

    Abstract translation: 本发明涉及对巨噬细胞迁移和/或巨噬细胞吞噬活性具有抑制作用的中枢神经系统衍生的热稳定免疫特异性因子。 此外，该因子对巨噬细胞和T细胞粘附于细胞外基质和/或纤连蛋白的能力产生抑制作用。 本发明还涉及使用这种免疫特权因子来抑制中枢神经系统中的中枢神经系统炎症和中枢神经系统特定病变的分离和方法。

    Nano-lithography using squeezed atomic and molecular states
    387.
    发明申请
    Nano-lithography using squeezed atomic and molecular states 失效
    使用挤压的原子和分子态进行纳米光刻

    公开(公告)号：US20030152841A1

    公开(公告)日：2003-08-14

    申请号：US10161541

    申请日：2002-06-03

    Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.

    Inventor： Eliyahu Averbukh

    IPC: G03H001/04

    CPC classification number: B82Y10/00 ,  B82Y40/00 ,  G03H1/0891 ,  H01J37/3174 ,  H01J2237/31735 ,  H01J2237/31752

    Abstract: A method and apparatus for performing atomic and molecular nano-deposition by means of atomic or molecular focusing through a plurality of optical standing waves. A stacked set of standing light waves, preferably arranged as gratings in a predetermined form and of predetermined intensities, is used to sequentially compress or squeeze the width of the incident atomic or molecular beam into ultra-narrow, spatially localized spots or lines. The result is a focused beam of particles with improved resolution compared with prior art atomic focusing. Furthermore, spherical and chromatic aberrational effects can be reduced.

    Abstract translation: 一种通过原子或分子聚焦通过多个光学驻波进行原子和分子纳米沉积的方法和装置。 使用堆叠的一组常规光波，优选地以预定形式布置为预定形式的光栅并且预定强度，以将入射的原子或分子束的宽度顺序地压缩或挤压成超狭窄的空间局部化的斑点或线。 结果是与现有技术的原子聚焦相比，聚焦的粒子束具有改进的分辨率。 此外，可以减少球面和色差效应。

    Anti-inflammatory peptides derived from C-reactive protein
    388.
    发明申请
    Anti-inflammatory peptides derived from C-reactive protein 失效
    衍生自C反应蛋白的抗炎肽

    公开(公告)号：US20030152564A1

    公开(公告)日：2003-08-14

    申请号：US10373794

    申请日：2003-02-27

    Applicant: Yeda Research and Development Co., Ltd. at the Weizmann Institute of Science

    Inventor： Matityahu Fridkin ,  Eran Yavin

    IPC: A61K038/55

    CPC classification number: C07K14/4737 ,  A61K38/00

    Abstract: A peptide corresponding to positions 62-71 of the sequence of human C-reactive protein (CRP) of the formula: Glu62-Ile-Leu-Ile-Phe-Trp-Ser-Lys-Asp-Ile71 and modifications thereof obtained by substitution, deletion, or addition of amino acids, amidation of the C-terminal or acylation of the N-terminal, are capable of inhibiting in vitro the enzymatic activity of human Leukocyte Elastase (hLE) and/or of human Cathepsin G (hCG) and can be used for the treatment of chronic inflammation conditions such as rheumatoid arthritis, pulmonary emphysema, cystic fibrosis, bronchitis, asthma and some acute respiratory distress syndrome.

    Abstract translation: 对应于下式的人C-反应蛋白（CRP）序列62-71的肽：Glu62-Ile-Leu-Ile-Phe-Trp-Ser-Lys-Asp-Ile71及其通过取代获得的修饰， 氨基酸的缺失或添加，C-末端的酰胺化或N末端的酰化，能够在体外抑制人白细胞弹性蛋白酶（hLE）和/或人组织蛋白酶G（hCG）的酶活性，并且可以 用于治疗慢性炎症病症如类风湿性关节炎，肺气肿，囊性纤维化，支气管炎，哮喘和一些急性呼吸窘迫综合征。

    Helianthrone derivatives as anti-cancer agents
    389.
    发明申请
    Helianthrone derivatives as anti-cancer agents 有权
    海龙龙衍生物作为抗癌剂

    公开(公告)号：US20030105357A1

    公开(公告)日：2003-06-05

    申请号：US10209427

    申请日：2002-07-30

    Applicant: Yeda Research And Development Co. Ltd.

    Inventor： Yehuda Mazur ,  Gad Lavie

    IPC: C07C239/00

    CPC classification number: A61K31/136 ,  A61K31/122 ,  A61K31/235

    Abstract: Hypericin, helianthrone and derivatives thereof of general formula (I) 1 wherein the dotted line between positions 11 and 12 represent an optional C11-C12 bond; R is independently selected from the group consisting of hydroxy, C1-C10 alkoxy, NHnullC1-C10 alkyl, and NH-hydroxy(C1-C10)alkyl; Rnull is independently selected from the group consisting of hydroxy and C1-C10 alkoxy; Rnull is independently selected from the group consisting of hydrogen, hydroxy, C1-C10 alkoxy, NHnullC1-C10 alkyl, and NH-hydroxy(C1-C10)alkyl; and R1, R2, R3, R4, R5 and R6 are independently selected from the group consisting of hydrogen, hydroxy, chloro, bromo, C1-C10 alkyl, C1-C10 alkoxy, and C1-C10 alkoxycarbonyl, provided that Rnull is not hydrogen when there is a C11-C12 bond, are useful as inhibitors of angiogenesis and can be used to prevent formation of metastases and restenosis and for the treatment of angiogenesis-associated ophthalmologic disorders. In addition, the helianthrones of formula (I) can be used for the treatment of tumors in the absence of light irradiation. New compounds include those of formula I which are other than hypericin and known hypericin derivatives and there is either a C11-C12 bond or at least one Rnull is other than hydrogen.

    Abstract translation: 通式（I）的金丝桃素，向日葵及其衍生物，其中位置11和12之间的虚线表示任选的C 11 -C 12键; R独立地选自羟基，C 1 -C 10烷氧基，NH-C 1 -C 10烷基和NH-羟基（C 1 -C 10）烷基; R'独立地选自羟基和C 1 -C 10烷氧基; R“独立地选自氢，羟基，C 1 -C 10烷氧基，NH-C 1 -C 10烷基和NH-羟基（C 1 -C 10）烷基; R 1，R 2，R 3，R 4，R 5和R 6独立地选自氢，羟基，氯，溴，C 1 -C 10烷基，C 1 -C 10烷氧基和C 1 -C 10烷氧基羰基，条件是R“ 当存在C11-C12键时，不是氢，可用作血管发生的抑制剂，可用于预防转移和再狭窄的形成以及用于治疗血管发生相关的眼科疾病。 此外，式（I）的长方体可用于在不存在光照射的情况下治疗肿瘤。 新化合物包括除金丝桃素和已知金丝桃素衍生物之外的式I的那些，并且存在C 11 -C 12键或至少一个R“不是氢。

Patent Agency Ranking